Vistagen Therapeutics Long Term Debt

Vistagen Therapeutics (VTGN) currently reports a long-term debt of $250K as of March 2026. That compares with $950K in the prior-year period — down 73.7% year over year. Use the charts on this page to explore Vistagen Therapeutics's long-term debt history and peer comparisons.

Vistagen Therapeutics's long-term debt decreased from $950K to $250K — a 73.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vistagen Therapeutics reported $250K in long-term debt as of March 2026. That compares with $950K in the prior-year period — down 73.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $250K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vistagen Therapeutics, and consider following VTGN for alerts when major investors trade the stock.

Vistagen Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $250K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VTGN with unrelated industries.